{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002655","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.454450+00:00","generated_at":"2026-06-07T02:13:57.872238+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ultragenyx reports preliminary 2023 revenue $430-435M; guides 2024 revenue $500-530M","bullets":["Preliminary 2023 total revenue $430-435M; Crysvita $325-330M, Dojolvi $70-71M.","2024 total revenue guidance $500-530M; Crysvita $375-400M, Dojolvi $75-80M.","Year-end 2023 cash ~$776M; 2024 net cash used in ops guided <$400M.","Phase 3 data readouts expected H1 2024 for GSDIa gene therapy (DTX401) and OI study enrollment completion."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002655","json":"https://secwatch.observer/filing/0000950170-24-002655.json","markdown":"https://secwatch.observer/filing/0000950170-24-002655.md","text":"https://secwatch.observer/filing/0000950170-24-002655.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024002655/0000950170-24-002655-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024002655/rare-20240107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:13:57.872238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"696158c96bd2f8c607ab12cdea2b11fa00490a9c","claim":"Ultragenyx Pharmaceutical Inc. reported fiscal year 2024 results: revenue $500 million to $530 million. Guidance initiated.","evidence_excerpt":"2024 expected Total Revenue guidance between $500 million to $530 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024002655/0000950170-24-002655-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2024"},{"label":"Revenue","value":"$500 million to $530 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"eb9b161703bee533632c540438bebebe65c77a59","claim":"Ultragenyx Pharmaceutical Inc. reported fiscal year 2023 results: revenue $430 million to $435 million.","evidence_excerpt":"Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $ 325 million to $330 million and Dojolvi® revenue of $70 million to $71 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024002655/0000950170-24-002655-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"$430 million to $435 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}